Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet

Ischaemic stroke despite antiplatelet therapy: Causes and outcomes

Practical “1-2-3-4-Day” Rule for Starting Direct Oral

Asundexian: an oral small molecule factor XIa inhibitor for the

PDF) Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke

Full article: Atrial fibrillation and stroke

Dual Antiplatelet Therapies and Causes in Minor Stroke or

Determination of the Potential Clinical Benefits of Small Molecule

Effects of Tablet Formulation, Food, or Gastric pH on the

JCDD, Free Full-Text

Anticoagulation

Factor XI/XIa inhibitors for the prevention and treatment of

Factor XIa Inhibitors: Quest for the Perfect Antithrombin Agents